Investors with losses are encouraged to contact the firm before November 21, 2020; click here to submit trade information
LOS ANGELES, Nov. 19, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Aimmune Therapeutics, Inc. (NASDAQ: AIMT) investors that acquired shares relating to the sale of the Company to Sociétés des Produits Nestlé, S.A. Investors have until November 21, 2020 to seek an active role in this litigation.
It was announced by Aimmune on August 31, 2020 that it had signed an agreement to be acquired by SNP for approximately $2.6 billion. Aimmune stockholders will receive $34.50 in cash for each share of Aimmune common stock owned, pursuant to the merger agreement. The deal is scheduled to be closed in the fourth quarter of 2020.
It is alleged in the complaint that Aimmune’s board of directors oversaw an unfair process and ultimately agreed to a merger agreement that was inadequate. Aimmune stock has recently traded at a price well above the merger consideration of $34.50.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 21, 2020.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.